ELYM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ELYM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Eliem Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.11. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.73.
During the past 3 years, the average EBIT per Share Growth Rate was -13.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Eliem Therapeutics's EBIT per Share or its related term are showing as below:
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Eliem Therapeutics was -13.90% per year. The lowest was -35.70% per year. And the median was -24.80% per year.
Eliem Therapeutics's EBIT for the three months ended in Mar. 2024 was $-3.01 Mil.
The historical data trend for Eliem Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eliem Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
EBIT per Share | -0.69 | -1.01 | -2.91 | -1.72 | -1.49 |
Eliem Therapeutics Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EBIT per Share | Get a 7-Day Free Trial | -0.89 | -0.25 | -0.19 | -0.19 | -0.11 |
EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.
Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.
Eliem Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as
EBIT per Share | (A: Dec. 2023 ) | ||
= | EBIT | / | Shares Outstanding (Diluted Average) | = | -40.275 | / | 26.987 |
= | -1.49 |
Eliem Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as
EBIT per Share | (Q: Mar. 2024 ) | ||
= | EBIT | / | Shares Outstanding (Diluted Average) | = | -3.005 | / | 27.639 |
= | -0.11 |
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eliem Therapeutics (NAS:ELYM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Thank you for viewing the detailed overview of Eliem Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Emily Pimblett | officer: Chief Accounting Officer | C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053 |
Ai Eti Llc | 10 percent owner | C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
Ra Capital Healthcare Fund Lp | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Judith Dunn | director | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Valerie Morisset | officer: Chief Scientific Officer | C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053 |
Andrew David Levin | director | C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053 |
Simon Tate | director | C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053 |
Adam Joseph Rosenberg | director | C/O ELIEM THERAPEUTICS, INC., 23515 NE NOVELTY HILL RD, STE B221 #125, REDMOND WA 98053 |
James B Bucher | officer: EVP and General Counsel | 11804 NORTH CREEK PARKWAY S, BOTHELL WA 98011 |
Ra Capital Nexus Fund Ii, L.p. | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Erin Lavelle | officer: COO & CFO | C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Ra Capital Nexus Fund, L.p. | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Len Blavatnik | other: Affiliate of 10% Owner | C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019 |
Liam Ratcliffe | director | C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019 |
Robert Azelby | director, officer: Chief Executive Officer | 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-17-2022
By PurpleRose PurpleRose • 07-15-2022
By GuruFocusNews GuruFocusNews • 06-27-2022
By Value_Insider Value_Insider • 11-08-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By sperokesalga sperokesalga • 05-11-2023
By GuruFocusNews GuruFocusNews • 06-05-2022
By GuruFocusNews GuruFocusNews • 05-26-2022
By PurpleRose PurpleRose • 07-18-2022
By GuruFocusNews GuruFocusNews • 07-07-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.